- Vienna 2018
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: S.Lee SOUTH KOREA
Co Author(s): E. Cho
Back to previous
To investigate the clinical results, recurrence rates, and recurrence-related risk factors of Conjunctivo-Limbal Autograft (CLAU) after excision of recurrent pterygium.
Yeungnam University Hospital, Daegu, South Korea
Recurrence grade was evaluated for 35 eyes with a mean follow-up of 32.5 months (range 6 to 96 months). Surgical results were classified into surgical success (G0/G1), conjunctival recurrence (G2), and corneal recurrence (G3). Occurrence rates over than G1 were analyzed based on gender, age, horizontal and vertical length of the preoperative pterygium, the corneal involvement size of the preoperative pterygium, a frequency of recurrence, presence of TAMP, limitation of EOM, and epithelial healing time. Using Kaplan-meier survival analysis, the cumulative proportion of integrated G0/G1 was evaluated.
In the postoperative grading, 33 (94.3%) eyes were graded as clinically recurrence-free G0 and G1, and 2 (5.7%) eyes were graded as clinically recurrence-occurred G2 (1eye) and G3 (1eye). There was no statistically significant difference in gender, age, horizontal and vertical length of the preoperative pterygium, the corneal involvement size of the preoperative pterygium, a frequency of recurrence, presence of TAMP, limitation of EOM, and epithelial healing time between G0 group and G1/G2/G3 group. The cumulative proportion of integrated recurrence-free G0/G1 at 5 years after surgery was 0.90 ±0.10.
The recurrence rate (5.7%) of this study showed compatible results with the recurrence rates (5.6 to 13.3%) in other studies. The CLAU has advantages of surgical procedure with ease, low complications, and low recurrence rates. Therefore, after surgical excision of recurrent pterygium, the authors concluded the CLAU is highly recommended for good clinical outcomes and low recurrence rates.